Fox Run Management L.L.C. Has $1.01 Million Holdings in RxSight, Inc. (NASDAQ:RXST)

Fox Run Management L.L.C. grew its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 47.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,458 shares of the company’s stock after purchasing an additional 9,443 shares during the period. Fox Run Management L.L.C. owned about 0.07% of RxSight worth $1,013,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new position in shares of RxSight during the 4th quarter worth approximately $213,000. Quantbot Technologies LP grew its position in shares of RxSight by 31.7% during the 4th quarter. Quantbot Technologies LP now owns 33,444 shares of the company’s stock worth $1,150,000 after purchasing an additional 8,041 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of RxSight by 53.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 352,626 shares of the company’s stock worth $12,124,000 after purchasing an additional 122,989 shares in the last quarter. Telemark Asset Management LLC grew its position in shares of RxSight by 6.6% during the 4th quarter. Telemark Asset Management LLC now owns 321,000 shares of the company’s stock worth $11,036,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of RxSight by 2.6% during the 4th quarter. Swiss National Bank now owns 66,300 shares of the company’s stock worth $2,279,000 after purchasing an additional 1,700 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $24.84 on Friday. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -29.93 and a beta of 1.22. The firm has a 50 day simple moving average of $29.63 and a 200 day simple moving average of $40.05. RxSight, Inc. has a one year low of $24.09 and a one year high of $66.54.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. As a group, analysts expect that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Activity at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. This represents a 22.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the completion of the transaction, the director now owns 7,383 shares of the company’s stock, valued at approximately $227,913.21. This trade represents a 32.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.36% of the stock is owned by insiders.

Analysts Set New Price Targets

RXST has been the topic of a number of analyst reports. JPMorgan Chase & Co. decreased their target price on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target on shares of RxSight in a report on Wednesday, February 26th. Wells Fargo & Company cut their price target on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. UBS Group initiated coverage on shares of RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 price target for the company. Finally, Bank of America cut their price target on shares of RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a report on Friday. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.33.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.